According to a recent market study published by Transparency Market Research (TMR), the global asthma and COPD market was worth USD 25,102.3 million in 2010, which is expected to reach USD 26,965.5 million in 2017 along with a CAGR figure of 1.03% over the forecasted period
The current asthma and COPD market is primarily driven by increasing patient population. It is also growing due to factors such as price erosion and expiry of patents of leading drug brands in the market. However, it is estimated that in the next five years, the global asthma and COPD drug market is expected to grow slowly and steadfast. In 2010, the asthma drug segment dominated the overall asthma and COPD market at USD 14,509.1 million. In the same year, the COPD segment was projected to be worth USD 10,593.2 million and is expected to reach USD 12,619.8 million in 2017.
Asthma being one of the most common disorders is defined as a respiratory condition that affects the airway system of our body wherein, the tubes that carry the air in and out of the body is inflamed and constricted due to one or more environmental triggers. Asthma is a type of a chronic disease, and if this potentially fatal condition is left untreated, there are chances for the condition to worsen making a person suffer from extreme respiratory problems to breathe the environmental air in any form.
People who suffer from the asthma attacks have swollen airways’ walls that get narrower when irritated causing sensations within their ENT area. This makes it difficult for the person to take in subsequent amount of air for a hassle-free inhale. Likewise, the airways' walls of the patients suffering from COPD are almost similar. Patients suffering from asthma and COPD conditions have airways’ walls inflamed with mucus.
Worldwide, over 300 million people suffer from asthma which has subsequently aggravated the drug market to reach a figure worth over $15 billion. Asthma can be treated by drug therapy or by avoiding environmental triggers.
In Europe, LABA / ICS combinations and LTA (Montelukast) drugs are more popular for asthma and COPD treatment. Merck's branded product Singulair contains Montelukast sodium, which is a leading oral anti-asthma and anti-allergy drug. Singulair is one of the trusted drugs for the treatment of chronic asthma, and for the relief of symptoms of seasonal allergic rhinitis. Currently, Montelukast is the largest selling anti-asthmatic drug worldwide.
For COPD patients, physicians also prescribe use of the long-acting muscarinic antagonist (LAMA) Spiriva (Boehringer Ingelheim/Pfizer). Spiriva is expected to constitute about xxx% of the U.S. COPD drug sales in 2012. The LABA/LAMA combination is preferred for the treatment of COPD. Several combinations are in late-stage development, including vilanterol / GSK-573719 (GlaxoSmithKline/Theravance), indacaterol / glycopyrronium (Novartis), and olodaterol / tiotropium (Boehringer Ingelheim).
Key products exposed to generic competition include GlaxoSmithKline’s Advair Boehringer Ingelheim/Pfizer’s Spiriva and Merck’s Singulair, which will lose active ingredient patent protection in the U.S. in 2011 and 2012 respectively. Patent expiration of Merck’s Singulair, which generated sales of around USD 3.3 billion in 2010, will be a key restraint for the overall Asthma market as generic entry in the United States, Europe and Japan will reduce sales of branded Singulair.
Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.